ANL 22.50 Decreased By ▼ -0.60 (-2.6%)
ASC 16.10 No Change ▼ 0.00 (0%)
ASL 21.80 Decreased By ▼ -0.45 (-2.02%)
BOP 8.58 Increased By ▲ 0.03 (0.35%)
BYCO 8.82 Decreased By ▼ -0.14 (-1.56%)
FCCL 17.62 Decreased By ▼ -0.45 (-2.49%)
FFBL 24.02 Decreased By ▼ -0.43 (-1.76%)
FFL 17.83 Decreased By ▼ -0.07 (-0.39%)
FNEL 8.44 Increased By ▲ 0.04 (0.48%)
GGGL 21.65 Decreased By ▼ -0.44 (-1.99%)
GGL 42.45 Decreased By ▼ -0.73 (-1.69%)
HUMNL 6.93 Decreased By ▼ -0.09 (-1.28%)
JSCL 20.50 Decreased By ▼ -0.35 (-1.68%)
KAPCO 37.80 Decreased By ▼ -0.10 (-0.26%)
KEL 3.53 Decreased By ▼ -0.08 (-2.22%)
MDTL 3.00 No Change ▼ 0.00 (0%)
MLCF 36.14 Decreased By ▼ -0.16 (-0.44%)
NETSOL 151.41 Decreased By ▼ -1.89 (-1.23%)
PACE 5.97 Decreased By ▼ -0.01 (-0.17%)
PAEL 30.95 Decreased By ▼ -0.25 (-0.8%)
PIBTL 9.31 Decreased By ▼ -0.05 (-0.53%)
POWER 7.86 Decreased By ▼ -0.04 (-0.51%)
PRL 20.46 Decreased By ▼ -0.39 (-1.87%)
PTC 10.39 Decreased By ▼ -0.01 (-0.1%)
SILK 1.65 Decreased By ▼ -0.02 (-1.2%)
SNGP 43.29 Increased By ▲ 0.10 (0.23%)
TELE 21.46 Decreased By ▼ -0.60 (-2.72%)
TRG 171.78 Decreased By ▼ -1.72 (-0.99%)
UNITY 35.80 Decreased By ▼ -0.40 (-1.1%)
WTL 3.19 Decreased By ▼ -0.06 (-1.85%)
BR100 4,940 Decreased By ▼ -38.7 (-0.78%)
BR30 24,198 Decreased By ▼ -262.46 (-1.07%)
KSE100 46,363 Decreased By ▼ -272.81 (-0.58%)
KSE30 18,329 Decreased By ▼ -151.79 (-0.82%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
27,246
4024hr
Pakistan Cases
1,226,008
2,16724hr
4.22% positivity
Sindh
450,787
Punjab
422,790
Balochistan
32,769
Islamabad
104,242
KPK
171,388
Business & Finance

J&J raises forecasts, estimates $2.5bn in COVID-19 vaccine sales

  • Pfizer and Moderna forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively
  • J&J raised its expectations for full-year sales to a range of $93.8 billion to $94.6 billion including contribution from the single-dose vaccine, and to $91.3 billion-$92.1 billion for the rest of the business
21 Jul 2021

Johnson & Johnson on Wednesday raised its overall revenue estimate for the year and forecast $2.5 billion in sales of its COVID-19 vaccine, which has fallen way behind rival shots from Pfizer and Moderna as the company deals with vaccine production issues and safety concerns.

Although Johnson & Johnson's shot was approved in the United States months after vaccines from Pfizer Inc and Moderna Inc, its vaccine outlook pales in comparison with its peers and reflects the widening gap in the vaccine race.

Pfizer and Moderna forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively.

The J&J shot, once touted as an important tool for vaccinations in hard-to-reach areas, has already delayed deliveries in the United States and Europe. It has also been linked to a very rare, potentially life-threatening blood-clotting condition.

J&J's says its Covid-19 vaccine effectively combats Delta variant

J&J raised its expectations for full-year sales to a range of $93.8 billion to $94.6 billion including contribution from the single-dose vaccine, and to $91.3 billion-$92.1 billion for the rest of the business.

It had previously forecast sales to come in between $90.6 billion and $91.6 billion.

The outlook was driven by recovery in sales at its medical devices unit and higher demand for treatments such as psoriasis and Crohn's disease drug Stelara.

The company had recorded $164 million in vaccine sales in for the second quarter.

Pfizer Inc and Moderna Inc have forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively. Both shots were approved in the United States last year, while J&J's vaccine was approved this year.

Both companies expect to profit from their vaccines, while Johnson & Johnson has said it will make the vaccine available on a not-for-profit basis during the pandemic.

Moderna, J&J to make up bulk of Germany's 2022 extra vaccine purchases

In the second quarter, J&J earned $2.48 per share, beating analysts' average estimate of $2.27 per share, according to IBES data from Refinitiv.

The company reported $23.31 billion in total sales, above the estimate of $22.21 billion.

Shares of the company rose 1% before the opening bell.

Comments

Comments are closed.